PLETOZ 50MG TABLET 10'S

PLETOZ 50MG TABLET 10'S's effects may vary from person to person. Some people may notice an improvement in their symptoms within a few weeks, while others may take longer. It is essential to follow the prescribed dosage and give it time to take effect.

If you miss a dose of PLETOZ 50MG TABLET 10'S, take it as soon as you remember. However, if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.

Common side effects of PLETOZ 50MG TABLET 10'S may include headache, diarrhea, abnormal stools, and palpitations. However, everyone may not experience these side effects. If you experience any unusual symptoms, contact your healthcare provider.

It is essential not to stop taking PLETOZ 50MG TABLET 10'S without consulting your healthcare provider, even if you feel better. Abruptly discontinuing the medication can lead to a return of symptoms or other health complications. Always follow your doctor's instructions regarding the duration of treatment.

PLETOZ 50MG TABLET 10'S is usually taken at least half an hour before or two hours after meals. Consult your healthcare provider or read the medication guide for specific instructions on administering this medication.

If you suspect an overdose of PLETOZ 50MG TABLET 10'S or experience symptoms such as severe dizziness, fainting, or difficulty breathing, seek immediate medical help. Contact a poison control center or visit the nearest emergency room for assistance.

PLETOZ 50MG TABLET 10'S can increase the risk of bleeding, so it is important to be cautious if you have a bleeding disorder or are taking other blood-thinning medications. It may also affect your heart and cause palpitations, so be watchful if you have any heart conditions. People with liver or kidney problems should use it carefully and may need adjustments in their dosage. If you have had recent surgery or have known allergies to it or any other medications, make sure to inform your doctor. It can interact with other medications, so let your healthcare provider know about all the drugs you are taking. If you have heart failure, a bleeding disorder, or are older, consult your doctor before taking this medication.

It is a good idea to consult your healthcare provider about consuming alcohol while taking this medication. Always follow your doctor's advice, and if you experience any unusual symptoms, let your doctor know immediately.

Cilostazol is a molecule used for making PLETOZ 50MG TABLET 10'S. It helps the medicine exert its effects.

PLETOZ 50MG TABLET 10'S is prescribed for cardiac conditions related to Cardiology.

PLETOZ 50MG TABLET 10'S is used for conditions related to Hematology.

Pletoz 50 is a prescription medicine containing cilostazol 50 mg as its active ingredient. Cilostazol is a phosphodiesterase III inhibitor with antiplatelet and vasodilatory properties. It is used mainly to improve walking distance in adults with intermittent claudication due to peripheral arterial disease by increasing blood flow to the legs.

Pletoz 50 is indicated for the symptomatic treatment of intermittent claudication in adults, a condition where reduced blood flow to the leg muscles causes pain or cramping during walking or exercise. By improving blood flow and reducing platelet aggregation, Pletoz 50 can increase pain-free walking distance. It is used as part of a broader management plan that includes lifestyle modification and control of cardiovascular risk factors.

Pletoz 50 (cilostazol) inhibits the enzyme phosphodiesterase III in platelets and vascular smooth muscle cells. This inhibition increases intracellular cAMP levels, leading to relaxation of vascular smooth muscle (vasodilation) and reduced platelet aggregation. The combined effect is improved microcirculation and blood flow in the peripheral arteries, which helps relieve symptoms of intermittent claudication and enhances exercise tolerance.

Pletoz 50 is not primarily indicated for the prevention of heart attack or stroke. Its approved use is for improving walking distance in intermittent claudication associated with peripheral arterial disease. Although cilostazol has antiplatelet effects, other antiplatelet agents are generally preferred and better established for primary or secondary prevention of cardiovascular and cerebrovascular events. Any off-label use must be determined by a specialist based on individual risk–benefit assessment.

Pletoz 50 is contraindicated in patients with any degree of heart failure, due to increased mortality seen with other phosphodiesterase III inhibitors in this population. It should also not be used in patients with known hypersensitivity to cilostazol or any excipient in the formulation, in those with active pathological bleeding, and generally in patients with severe arrhythmias, unstable angina, recent myocardial infarction, or severe hypotension or uncontrolled hypertension, unless a specialist judges that potential benefits outweigh risks.

Common side effects of Pletoz 50 include headache, diarrhoea, palpitations, dizziness, peripheral oedema, abdominal pain, dyspepsia, and tachycardia. Some patients may also experience nausea, vomiting, or flushing. These adverse effects are often dose-related and may improve with continued therapy. However, any persistent, severe, or concerning symptoms, especially chest pain, shortness of breath, fainting, or signs of bleeding, require prompt medical evaluation.

Pletoz 50 has antiplatelet activity and may be used in combination with other antiplatelet agents such as aspirin or clopidogrel in selected patients, but this increases the risk of bleeding. Such combinations should only be used under close medical supervision, with careful assessment of bleeding risk versus potential benefit. Patients should be advised to report any signs of bleeding, such as unusual bruising, nosebleeds, blood in urine or stools, or prolonged bleeding from cuts.

Cilostazol is metabolised in the liver and its metabolites are excreted partly via the kidneys. In patients with moderate to severe hepatic impairment or significant renal dysfunction, exposure to the drug and its metabolites may be altered, potentially increasing the risk of adverse effects. Use of Pletoz 50 in such patients requires caution, possible dose adjustment as per the prescriber’s judgement, and close monitoring. In severe hepatic impairment, cilostazol is generally not recommended.

Data on the use of cilostazol in pregnant women are limited, and animal studies have shown reproductive toxicity at high exposures. Therefore, Pletoz 50 is not recommended during pregnancy unless the potential benefit to the mother clearly outweighs the potential risk to the fetus, and this decision must be made by a specialist. It is not known whether cilostazol or its metabolites are excreted in human breast milk. Because of the potential for serious adverse reactions in the breastfed infant, use during breastfeeding is generally discouraged, and an alternative therapy or discontinuation of breastfeeding should be considered.

Clinical improvement with Pletoz 50 is not immediate. Some patients may notice an increase in pain-free walking distance within a few weeks, but maximal benefit is often observed after several weeks to a few months of continuous therapy. Treatment response should be reassessed periodically, and if there is no meaningful improvement after an adequate trial period, the prescriber may consider discontinuing the drug or exploring alternative options.

Pletoz 50 can cause dizziness, headache, and, less commonly, visual disturbances in some individuals. These effects may impair the ability to drive or operate machinery safely. Patients should observe how they react to the medicine before engaging in such activities. If dizziness, light-headedness, or visual symptoms occur, they should avoid driving or operating potentially dangerous machinery and consult their healthcare provider.

Yes. Pletoz 50 (cilostazol) is metabolised mainly by CYP3A4 and CYP2C19. Strong inhibitors of these enzymes, such as certain azole antifungals, macrolide antibiotics, or some proton pump inhibitors, can increase cilostazol levels and may raise the risk of adverse effects. Enzyme inducers can reduce its effectiveness. Concomitant use with other antiplatelet agents, anticoagulants, or nonsteroidal anti-inflammatory drugs can increase bleeding risk. Patients should inform their healthcare provider about all prescription medicines, over-the-counter drugs, and herbal supplements they are taking before starting Pletoz 50.